311 related articles for article (PubMed ID: 37035206)
21. Uncoupling between Ig somatic hypermutation and oncogene mutation in mouse lymphoma.
Vincent C; Truffinet V; Fiancette R; Petit B; Cogné N; Cogné M; Denizot Y
Biochim Biophys Acta; 2009 Feb; 1793(2):418-26. PubMed ID: 19026697
[TBL] [Abstract][Full Text] [Related]
22. MYC in Germinal Center-derived lymphomas: Mechanisms and therapeutic opportunities.
Bisso A; Sabò A; Amati B
Immunol Rev; 2019 Mar; 288(1):178-197. PubMed ID: 30874346
[TBL] [Abstract][Full Text] [Related]
23. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
24. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Xu-Monette ZY; Dabaja BS; Wang X; Tu M; Manyam GC; Tzankov A; Xia Y; Zhang L; Sun R; Visco C; Dybkaer K; Yin L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Zhao X; Winter JN; Piris MA; McDonnell TJ; Miranda RN; Li Y; Medeiros LJ; Young KH
Mod Pathol; 2015 Dec; 28(12):1555-73. PubMed ID: 26541272
[TBL] [Abstract][Full Text] [Related]
25. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.
Havelange V; Ameye G; Théate I; Callet-Bauchu E; Mugneret F; Michaux L; Dastugue N; Penther D; Barin C; Collonge-Rame MA; Baranger L; Terré C; Nadal N; Lippert E; Laï JL; Cabrol C; Tigaud I; Herens C; Hagemeijer A; Raphael M; Libouton JM; Poirel HA;
Genes Chromosomes Cancer; 2013 Jan; 52(1):81-92. PubMed ID: 23012230
[TBL] [Abstract][Full Text] [Related]
26. Myc suppression of Nfkb2 accelerates lymphomagenesis.
Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
[TBL] [Abstract][Full Text] [Related]
27. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
[TBL] [Abstract][Full Text] [Related]
28. Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.
Heerma van Voss MR; Vesuna F; Trumpi K; Brilliant J; Berlinicke C; de Leng W; Kranenburg O; Offerhaus GJ; Bürger H; van der Wall E; van Diest PJ; Raman V
Oncotarget; 2015 Sep; 6(29):28312-26. PubMed ID: 26311743
[TBL] [Abstract][Full Text] [Related]
29. Determining the Origin of Human Germinal Center B Cell-Derived Malignancies.
Seifert M; Küppers R
Methods Mol Biol; 2017; 1623():253-279. PubMed ID: 28589362
[TBL] [Abstract][Full Text] [Related]
30. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
31. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
[TBL] [Abstract][Full Text] [Related]
32. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
33. Dysregulated expressions of PTEN, NF-κB, WWP2, p53 and c-Myc in different subtypes of B cell lymphoma and reactive follicular hyperplasia.
Fu H; Jin C; Zhu Q; Liu T; Ke B; Li A; Zhang T
Am J Transl Res; 2019; 11(2):1092-1101. PubMed ID: 30899409
[TBL] [Abstract][Full Text] [Related]
34. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.
Gormley RP; Madan R; Dulau AE; Xu D; Tamas EF; Bhattacharyya PK; LeValley A; Xue X; Kumar P; Sparano J; Ramesh KH; Pulijaal V; Cannizzaro L; Walsh D; Ioachim HL; Ratech H
Am J Clin Pathol; 2005 Nov; 124(5):790-8. PubMed ID: 16203284
[TBL] [Abstract][Full Text] [Related]
35. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.
Shams TM
J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842
[TBL] [Abstract][Full Text] [Related]
36. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma.
Gonin J; Larousserie F; Bastard C; Picquenot JM; Couturier J; Radford-Weiss I; Dietrich C; Brousse N; Vacher-Lavenu MC; Devergne O
PLoS One; 2011; 6(9):e24617. PubMed ID: 21931777
[TBL] [Abstract][Full Text] [Related]
38. Molecular characterization of the DDX3Y gene and its homologs in cattle.
Liu WS; Wang A; Yang Y; Chang TC; Landrito E; Yasue H
Cytogenet Genome Res; 2009; 126(4):318-28. PubMed ID: 20016128
[TBL] [Abstract][Full Text] [Related]
39. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.
Rodig SJ; Kutok JL; Paterson JC; Nitta H; Zhang W; Chapuy B; Tumwine LK; Montes-Moreno S; Agostinelli C; Johnson NA; Ben-Neriah S; Farinha P; Shipp MA; Piris MA; Grogan TM; Pileri SA; Gascoyne RD; Marafioti T
Haematologica; 2010 Dec; 95(12):2056-62. PubMed ID: 20823132
[TBL] [Abstract][Full Text] [Related]
40. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
